Opko Health Inc (OPK)

$1.22 -0.01 (-0.81%)
Market Cap 928.76M
Revenue (ttm) 606.88M
Net Income (ttm) -225.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37.19%
Debt to Equity Ratio 0.21
Volume 3,136,900
Avg Vol 2,818,088
Day's Range N/A - N/A
Shares Out 755.09M
Stochastic %K 8%
Beta 1.48
Analysts Sell
Price Target $2.62

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 305 575 4100
Address:
4400 Biscayne Boulevard, Miami, United States
Gasbagger
Gasbagger Jul. 14 at 9:33 PM
$OPK They still owe the Israeli Gvt a 250 MILLION DOLLAR Tax Bill plus interest !!! Ouch !
0 · Reply
Mike18181
Mike18181 Jul. 14 at 4:47 PM
$OPK Promotion because there is no Motion in Eanings. Promotion wore off ! CORPSE stock. Under 1.00 is coming soon.. " we expect BRL to turn a profit.🤣 Benjamin Netanyahu is honest ..👹
0 · Reply
Gasbagger
Gasbagger Jul. 14 at 4:43 PM
$OPK What happened to the Golden Cross ? Who was posting that ? Looks like it was more like a golden chower .
1 · Reply
Gasbagger
Gasbagger Jul. 14 at 3:58 PM
$OPK tymtested this morning posted this is a HUGE BUYING OPPRTUNITY? So did she buy some Opko this morning? How many other times as she made this same exact post? Did she buy then? I guarantee you if you ask her what her cost basis is, she won't tell you. Common sense says, if she posts Opko is a HUGE BUYING OPPURTUNITY, she would be buying.
0 · Reply
tradertrash
tradertrash Jul. 14 at 3:12 PM
$OPK 💩
0 · Reply
magadog
magadog Jul. 14 at 2:21 PM
$OPK not so sure the weakness is associated with the Same old iissues Ie: Frosty, BOD, incompetence, etc . Seems to me they were dragged by the market undercurrent. I know, why, , doesn’t matter, the results are the same
0 · Reply
tymtested
tymtested Jul. 14 at 11:03 AM
$OPK market is pricing opko as total failure,past,present and future. I ,for at least one, don’t align with that narrative. Any one of the numerous projects will more than double the stock price. HUGE BUYING OPPORTUNITY! GO OPKO!
1 · Reply
Gasbagger
Gasbagger Jul. 14 at 1:33 AM
$OPK Richard Phenniger is also in charge of Opko's Audit Committee. I wonder when the last time he went to Confession? He is also Vice Chairmen of Phillip and Patricia Frost Museum of Science. So, Frost has made Richard a Millionaire, a few times over. They will never turn their back on each other. Unless it is in Prison. Wink Wink !
1 · Reply
Mike18181
Mike18181 Jul. 13 at 11:22 PM
$OPK Richard Phenniger director, Scum.
1 · Reply
Brasil07
Brasil07 Jul. 13 at 8:02 PM
$OPK Monster share Indeed....
1 · Reply
Latest News on OPK
OPKO Health Transcript: AGM 2026

Jun 18, 2026, 10:00 AM EDT - 26 days ago

OPKO Health Transcript: AGM 2026

Entera Bio and Opko Health present preclinical data for oral peptides

2026-06-16T13:36:09.000Z - 4 weeks ago

Entera Bio and Opko Health present preclinical data for oral peptides

ENTX

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

Jun 15, 2026, 8:00 AM EDT - 4 weeks ago

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

OPKO Health Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 5 weeks ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2026

OPKO Health Proxy statement: Proxy filing

May 15, 2026, 8:00 AM EDT - 2 months ago

OPKO Health Proxy statement: Proxy filing

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

May 12, 2026, 8:00 AM EDT - 2 months ago

OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

OPKO Health Slides: Corporate presentation

May 8, 2026, 7:00 AM EDT - 2 months ago

OPKO Health Slides: Corporate presentation

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

Apr 30, 2026, 8:30 AM EDT - 2 months ago

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

Apr 30, 2026, 8:00 AM EDT - 2 months ago

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

OPKO Health Proxy statement: Proxy filing

OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

OPKO Health Proxy statement: Proxy filing

Opko Health downgraded to Market Perform from Outperform at Barrington

2026-04-29T12:37:59.000Z - 2 months ago

Opko Health downgraded to Market Perform from Outperform at Barrington

OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Earnings Call Transcript: Q1 2026

OPKO Health Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Earnings release: Q1 2026

OPKO Health Quarterly report: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 2 months ago

OPKO Health Quarterly report: Q1 2026

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

Apr 28, 2026, 4:05 PM EDT - 2 months ago

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Apr 22, 2026, 8:00 AM EDT - 3 months ago

OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

Apr 21, 2026, 4:05 PM EDT - 3 months ago

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

Opko Health price target lowered to $1.50 from $2.25 at Barrington

2026-03-02T14:20:11.000Z - 4 months ago

Opko Health price target lowered to $1.50 from $2.25 at Barrington

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

Feb 27, 2026, 8:00 AM EST - 4 months ago

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit

OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Earnings Call Transcript: Q4 2025

OPKO Health Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Annual report: Q4 2025

OPKO Health Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

OPKO Health Earnings release: Q4 2025

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Feb 26, 2026, 4:05 PM EST - 4 months ago

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

Feb 12, 2026, 8:00 AM EST - 5 months ago

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet

2026-02-04T13:16:35.000Z - 5 months ago

Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet

ENTX

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

Feb 4, 2026, 8:00 AM EST - 5 months ago

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 6 months ago

OPKO Health Transcript: 44th Annual J.P. Morgan Healthcare Conference

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:11 PM EST - 6 months ago

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

OPKO Health Slides: Corporate presentation

Nov 26, 2025, 7:00 AM EST - 8 months ago

OPKO Health Slides: Corporate presentation

Opko Health initiated with a Neutral at JPMorgan

2025-11-20T09:50:09.000Z - 8 months ago

Opko Health initiated with a Neutral at JPMorgan

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 4:05 PM EST - 8 months ago

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

Opko Health downgraded to Hold from Buy at Jefferies

2025-10-30T20:10:16.000Z - 9 months ago

Opko Health downgraded to Hold from Buy at Jefferies

Opko Health reports Q3 EPS 3c, consensus (5c)

2025-10-29T20:36:22.000Z - 9 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)

OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 9 months ago

OPKO Health Earnings Call Transcript: Q3 2025

OPKO Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 9 months ago

OPKO Health Quarterly report: Q3 2025

OPKO Health Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 9 months ago

OPKO Health Earnings release: Q3 2025

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

Oct 29, 2025, 4:05 PM EDT - 9 months ago

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

Opko Health’s ModeX enters license, collab agreement with Regeneron

2025-10-29T12:10:25.000Z - 9 months ago

Opko Health’s ModeX enters license, collab agreement with Regeneron

REGN

Opko Health’s ModeX Therapeutics begins trial of MDX2004

2025-10-28T12:21:29.000Z - 9 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Oct 22, 2025, 4:05 PM EDT - 9 months ago

OPKO Health to Report Third Quarter 2025 Financial Results on October 29

Opko Health management to meet with Barrington

2025-09-22T12:00:42.000Z - 10 months ago

Opko Health management to meet with Barrington

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Sep 15, 2025, 8:30 AM EDT - 10 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

LH

OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q2 2025

OPKO Health Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q2 2025

OPKO Health Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q2 2025

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

Jul 31, 2025, 4:05 PM EDT - 1 year ago

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

NextPlat Issues Interim CEO Update Shareholder Letter

Jun 30, 2025, 8:01 AM EDT - 1 year ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Jun 25, 2025, 11:00 AM EDT - 1 year ago

OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium

Entera Bio, Opko Health announce new in vivo data for OPK-88006

2025-06-25T12:10:46.000Z - 1 year ago

Entera Bio, Opko Health announce new in vivo data for OPK-88006

ENTX

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

2025-06-25T12:10:37.000Z - 1 year ago

Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025

ENTX

Opko Health’s ModeX forms Scientific Advisory Board

2025-06-09T12:21:02.000Z - 1 year ago

Opko Health’s ModeX forms Scientific Advisory Board

OPKO Health Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 11:05 AM EDT - 1 year ago

OPKO Health Transcript: Jefferies Global Healthcare Conference 2025

OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 9:00 AM EDT - 1 year ago

OPKO Health Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

OPKO Health to Participate in Two Upcoming Investor Conferences

May 15, 2025, 8:00 AM EDT - 1 year ago

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025

OPKO Health Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q1 2025

OPKO Health Earnings release: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q1 2025

Opko Health initiated with a Neutral at JPMorgan

2025-04-25T09:15:19.000Z - 1 year ago

Opko Health initiated with a Neutral at JPMorgan

Opko Health board authorizes $100M increase to existing share repurchase program

2025-04-04T12:10:48.000Z - 1 year ago

Opko Health board authorizes $100M increase to existing share repurchase program

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Apr 4, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program

Opko Health management to meet with Piper Sandler

2025-03-25T18:57:10.000Z - 1 year ago

Opko Health management to meet with Piper Sandler

OPKO and Entera partner to develop obesity pill

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill

OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

LH

OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024

OPKO Health Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Annual report: Q4 2024

OPKO Health Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q4 2024

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

Feb 27, 2025, 4:10 PM EST - 1 year ago

OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results

OPKO Health Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

OPKO Health Slides: FY 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Slides: FY 2025

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 11:45 AM EST - 1 year ago

OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

OPKO Health Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 1:30 PM EST - 1 year ago

OPKO Health Transcript: Piper Sandler 36th Annual Healthcare Conference

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

Nov 18, 2024, 8:00 AM EST - 1 year ago

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

NXPL

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

Nov 14, 2024, 6:00 AM EST - 1 year ago

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

BABA NXPL

OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024

OPKO Health Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Quarterly report: Q3 2024

OPKO Health Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q3 2024

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

Oct 7, 2024, 8:00 AM EDT - 1 year ago

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

Oct 7, 2024, 8:00 AM EDT - 1 year ago

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

NXPL

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

LH

OPKO Health Proxy statement: Proxy Filing

Aug 30, 2024, 8:00 AM EDT - 2 years ago

OPKO Health Proxy statement: Proxy Filing

OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q2 2024

OPKO Health Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q2 2024

OPKO Health Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q2 2024

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 7, 2024, 4:06 PM EDT - 2 years ago

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

Jul 17, 2024, 4:14 PM EDT - 2 years ago

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

OPKO Health Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 10:30 AM EDT - 2 years ago

OPKO Health Transcript: Jefferies 2024 Global Healthcare Conference

OPKO Health to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 10:48 AM EDT - 2 years ago

OPKO Health to Participate in the Jefferies Global Healthcare Conference

OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024

OPKO Health Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q1 2024

OPKO Health Earnings release: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q1 2024

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

May 7, 2024, 4:05 PM EDT - 2 years ago

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

LH

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Mar 5, 2024, 8:52 AM EST - 2 years ago

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

OPKO Health Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023

OPKO Health Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Annual report: Q4 2023

OPKO Health Earnings release: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q4 2023

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Feb 22, 2024, 4:05 PM EST - 2 years ago

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

OPKO Health Proxy statement: Proxy Filing

Feb 16, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing

OPKO Health Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 10, 2024, 6:45 PM EST - 2 years ago

OPKO Health Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

Jan 9, 2024, 4:05 PM EST - 2 years ago

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 4, 2024, 11:31 PM EST - 2 years ago

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Jan 3, 2024, 5:05 PM EST - 2 years ago

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

Nov 28, 2023, 7:00 AM EST - 2 years ago

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

Nov 7, 2023, 6:45 AM EST - 2 years ago

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

SOPH

OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q3 2023

OPKO Health Quarterly report: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Quarterly report: Q3 2023

OPKO Health Earnings release: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q3 2023

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Nov 2, 2023, 10:00 AM EDT - 2 years ago

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Oct 25, 2023, 4:25 PM EDT - 2 years ago

OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Sep 28, 2023, 4:08 PM EDT - 3 years ago

ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

OPKO Health Earnings Call Transcript: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings Call Transcript: Q2 2023

OPKO Health Quarterly report: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Quarterly report: Q2 2023

OPKO Health Earnings release: Q2 2023

Aug 3, 2023, 4:30 PM EDT - 3 years ago

OPKO Health Earnings release: Q2 2023

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 25, 2023, 4:05 PM EDT - 3 years ago

OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

Gasbagger
Gasbagger Jul. 14 at 9:33 PM
$OPK They still owe the Israeli Gvt a 250 MILLION DOLLAR Tax Bill plus interest !!! Ouch !
0 · Reply
Mike18181
Mike18181 Jul. 14 at 4:47 PM
$OPK Promotion because there is no Motion in Eanings. Promotion wore off ! CORPSE stock. Under 1.00 is coming soon.. " we expect BRL to turn a profit.🤣 Benjamin Netanyahu is honest ..👹
0 · Reply
Gasbagger
Gasbagger Jul. 14 at 4:43 PM
$OPK What happened to the Golden Cross ? Who was posting that ? Looks like it was more like a golden chower .
1 · Reply
Gasbagger
Gasbagger Jul. 14 at 3:58 PM
$OPK tymtested this morning posted this is a HUGE BUYING OPPRTUNITY? So did she buy some Opko this morning? How many other times as she made this same exact post? Did she buy then? I guarantee you if you ask her what her cost basis is, she won't tell you. Common sense says, if she posts Opko is a HUGE BUYING OPPURTUNITY, she would be buying.
0 · Reply
tradertrash
tradertrash Jul. 14 at 3:12 PM
$OPK 💩
0 · Reply
magadog
magadog Jul. 14 at 2:21 PM
$OPK not so sure the weakness is associated with the Same old iissues Ie: Frosty, BOD, incompetence, etc . Seems to me they were dragged by the market undercurrent. I know, why, , doesn’t matter, the results are the same
0 · Reply
tymtested
tymtested Jul. 14 at 11:03 AM
$OPK market is pricing opko as total failure,past,present and future. I ,for at least one, don’t align with that narrative. Any one of the numerous projects will more than double the stock price. HUGE BUYING OPPORTUNITY! GO OPKO!
1 · Reply
Gasbagger
Gasbagger Jul. 14 at 1:33 AM
$OPK Richard Phenniger is also in charge of Opko's Audit Committee. I wonder when the last time he went to Confession? He is also Vice Chairmen of Phillip and Patricia Frost Museum of Science. So, Frost has made Richard a Millionaire, a few times over. They will never turn their back on each other. Unless it is in Prison. Wink Wink !
1 · Reply
Mike18181
Mike18181 Jul. 13 at 11:22 PM
$OPK Richard Phenniger director, Scum.
1 · Reply
Brasil07
Brasil07 Jul. 13 at 8:02 PM
$OPK Monster share Indeed....
1 · Reply
Zerrat
Zerrat Jul. 13 at 8:01 PM
$OPK same old. Lol
1 · Reply
Gasbagger
Gasbagger Jul. 13 at 4:41 PM
$OPK Yvonne Briggs of Opko's Investor Relations Firm is now working for Core IR. HMMMMMMMMMMM !! She was useless anyways.
1 · Reply
Brasil07
Brasil07 Jul. 13 at 4:30 PM
$OPK the only reason that cause this avalanche of selling have a name and a surname Philip Frost, 90 years old of disgrace for shareholders!
1 · Reply
tymtested
tymtested Jul. 13 at 2:36 PM
$OPK looks like the market is daring OPKO to complete the stock buyback program. GO OPKO!
1 · Reply
Gasbagger
Gasbagger Jul. 13 at 2:35 PM
$OPK down again ,who which clown will be the first to call this a buying oppurtunity ?
2 · Reply
BULLSWIN75
BULLSWIN75 Jul. 13 at 2:34 PM
$OPK obvious the shorts are controlling the narrative here for past few years.. but mark my words, change is coming and they better cover their rear ends…………..
0 · Reply
Gasbagger
Gasbagger Jul. 13 at 1:44 AM
$OPK down another 3 pennies overnight. Common sense says if ModeX had anything Opko would be trading much higher . Its called the R&D hustle !
0 · Reply
Gasbagger
Gasbagger Jul. 11 at 8:54 PM
$OPK the pipeline is more like a pipedream. Phase 1=R&D money grab. Phase 2=Bigger R&D money grab. Thats if they even get there. Poster Presentation=R&D money grab !
0 · Reply
TommyCotton
TommyCotton Jul. 11 at 12:30 PM
$OPK All well and good, but a pipeline means nothing except that you’re spending alot of money. Results are what matter. If they dont have good to great data from their “advanced” pipeline in the coming months there will be little chance OPK ever becomes a good company—much less great. I think they have one last shot at this and it’s do or die.
2 · Reply
Zerrat
Zerrat Jul. 10 at 9:18 PM
$OPK the familiar finger pattern over and over. Lol
1 · Reply
Gasbagger
Gasbagger Jul. 10 at 4:08 PM
$OPK ModeX is worthless .Key Word STRUGGLED !!!!!! Zerhouni has been Sanofi's head of global research and development (R&D) for the past nine years. During his tenure he took steps to improve R&D productivity, but Sanofi has still struggled to find enough new products to offset the impact of weak diabetes drug sales, prompting the company to seek growth from outside.
0 · Reply
Brasil07
Brasil07 Jul. 10 at 3:58 PM
$OPK Epic Fury!!!!!
1 · Reply